U.S. Markets open in 2 mins
  • Crude Oil

    -0.05 (-0.07%)
  • Gold

    -9.80 (-0.55%)
  • Silver

    +0.46 (+2.05%)

    -0.0034 (-0.2924%)
  • 10-Yr Bond

    +0.0120 (+0.91%)
  • Vix

    -3.49 (-14.33%)

    -0.0045 (-0.3282%)

    +0.5600 (+0.5127%)

    +1,343.09 (+3.18%)
  • CMC Crypto 200

    +49.07 (+4.72%)
  • FTSE 100

    +102.39 (+1.47%)
  • Nikkei 225

    -200.31 (-0.67%)

Predictive Technology Group, Inc. (PRED) Announces Acquisition of LifeCode Genetics, Inc.

VIRGINIA BEACH, VA--(Marketwired - January 26, 2016) - Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding Company, announces that it acquired LifeCode Genetics, Inc. ("LifeCode"). LifeCode, a Nevada corporation established in 2011, develops and commercializes gene-based diagnostics.

LifeCode holds strategic gene-based diagnostic assets, which can assist mothers in having healthier pregnancies and, ultimately, healthier babies.

Bradley Robinson, President, Predictive Technology Group, Inc., states, "This acquisition complements the business strategy at PRED. We look for novel assets which can improve quality of human life."

Through an equity transaction, LifeCode is now a fully owned subsidiary of Predictive Technology Group, Inc.

PRED's mission of revolutionizing patient care through novel gene-based companion diagnostics and therapeutics continues forward with the acquisition of LifeCode Genetics, Inc.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases' onsets and progressions. PRED's subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.